UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/689,576	10/20/2003	Dario Renato Alessi	002.00022 (MEDY/P17930US)	8451

7590 03/15/2006

Karla M. Weyand
Rogalskyj & Weyand, LLP
PO Box 44
Livonia, NY 14487-0044

EXAMINER	
RAMIREZ, DELIA M	

ART UNIT	PAPER NUMBER
1652	

DATE MAILED: 03/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/689,576	ALESSI, DARIO RENATO	
	Examiner	Art Unit	
	Delia M. Ramirez	1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) 1-35 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☐ Claim(s) _____ is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☒ Claim(s) 1-35 are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: _____.

DETAILED ACTION

Status of the Application

Claims 1-35 are pending.

It is noted that there are no claims 18-19, 35 in the listing of claims submitted on 10/20/2003. As set forth in 37 CFR 1.126, claims must be numbered in consecutive order. Thus, claims 20-34, 36-38 have been renumbered 18-35 in accordance with 37 CFR 1.126. The Examiner has also taken into consideration the renumbering of the claims when determining their subject matter. For example, while prior claim 21 (now claim 19) refers to "a method according to claim 20", the Examiner has interpreted the claim to read "a method according to claim 18". Applicants are requested to (1) carefully review the claims and amend the text of those claims which use the original numbering of the claims to reflect the renumbering of the claims, and (2) take into consideration the renumbering of the claims throughout the prosecution of the instant application.

Renumbered claim 28 (previous claim 30) is missing a number after the term " SEQ ID NO:". Renumbered claims 33-35 (previous claims 36-38) refer to a polypeptide encoding the protein of claims 32-34. In the interest of advancing prosecution, for restriction purposes, the Examiner has assumed that the intended number in claim 28 is "SEQ ID NO: 5", and that the intended subject matter of claims 33-35 is a "polynucleotide encoding the protein of claims 32-34".

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:

   I. Claims 1-9, 17, 28, 30-32, drawn in part to a protein comprising SEQ ID NO: 3, classified in class 435, subclass 194.

   II. Claims 1-9, 17, 28, 30-32, drawn in part to a protein comprising SEQ ID NO: 4, classified in class 435, subclass 194.

III. Claims 1-9, 17, 28, 30-32, drawn in part to a protein comprising SEQ ID NO: 5, classified in class 435, subclass 194.

IV. Claims 10-15, 33-35, drawn in part to a polynucleotide encoding a protein comprising SEQ ID NO: 3, classified in class 536, subclass 23.2.

V. Claims 10-15, 33-35, drawn in part to a polynucleotide encoding a protein comprising SEQ ID NO: 4, classified in class 536, subclass 23.2.

VI. Claims 10-15, 33-35, drawn in part to a polynucleotide encoding a protein comprising SEQ ID NO: 5, classified in class 536, subclass 23.2.

VII. Claim 16, drawn in part to a method of purifying a protein comprising SEQ ID NO: 3, classified in class 530, subclass 412.

VIII. Claim 16, drawn in part to a method of purifying a protein comprising SEQ ID NO: 4, classified in class 530, subclass 412.

IX. Claim 16, drawn in part to a method of purifying a protein comprising SEQ ID NO: 5, classified in class 530, subclass 412.

X. Claims 18-23, 26, drawn in part to a method of identifying a modulator of a protein comprising SEQ ID NO: 3, classified in class 435, subclass 15.

XI. Claims 18-23, 26, drawn in part to a method of identifying a modulator of a protein comprising SEQ ID NO: 4, classified in class 435, subclass 15.

XII. Claims 18-23, 26, drawn in part to a method of identifying a modulator of a protein comprising SEQ ID NO: 5, classified in class 435, subclass 15.

XIII. Claims 24-25, drawn in part to a method of identifying a compound which mimics the effect of a 3-phosphoinositide on a protein comprising SEQ ID NO: 3, classified in class 435, subclass 15.

XIV. Claims 24-25, drawn in part to a method of identifying a compound which mimics the effect of a 3-phosphoinositide on a protein comprising SEQ ID NO: 4, classified in class 435, subclass 15.

XV. Claims 24-25, drawn in part to a method of identifying a compound which mimics the effect of a 3-phosphoinositide on a protein comprising SEQ ID NO: 5, classified in class 435, subclass 15.

XVI. Claims 27, 29, drawn in part to a method to activate protein kinase B with a protein comprising SEQ ID NO: 3, classified in class 435, subclass 15.

XVII. Claims 27, 29, drawn in part to a method to activate protein kinase B with a protein comprising SEQ ID NO: 4, classified in class 435, subclass 15.

XVIII. Claims 27, 29, drawn in part to a method to activate protein kinase B with a protein comprising SEQ ID NO: 5, classified in class 435, subclass 15.

The inventions are distinct, each from the other because of the following reasons:

2. Groups I-VI each comprise a chemically unrelated structure capable of separate manufacture, use, and effect. The nucleic acids of Groups IV-VI comprise purine and pyrimidine units, and the proteins of Groups I-III comprise amino acids, thus being structurally distinct molecules. The nucleic acids of Groups IV-VI have other uses besides encoding the proteins of Groups IV-VI, such as a hybridization probe or in gene therapy. Further, the proteins of Groups IV-VI can be prepared by processes which are materially different from recombinant expression of the nucleic acids of Groups IV-VI, such as by chemical synthesis, or by isolation and purification from natural sources.

3. The inventions of Groups I-VI are members of an improper Markush group as the proteins of Groups I-III do not have unity of invention according to MPEP § 803.02. Each of the proteins of Groups I-III comprise an unrelated amino acid sequence. As such, each of the proteins of Groups I-III can elicit different antibodies. Similarly, the nucleic acids of Groups IV-VI comprise an unrelated nucleic acid

sequence as they encode proteins having unrelated amino acid sequences. As such, each of the nucleic acids of Groups IV-VI can be used to probe different targets. Therefore, there is no unity of invention within the members of the Markush group as there is no shared common utility and there is no shared substantial structural feature disclosed as being essential to that utility.

4. Inventions I-III and X-XVIII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the proteins of Inventions I-III can be used in the materially different processes of Inventions X-XII (method of identifying a modulator), Inventions XIII-XV (method of identifying a compound which mimics the effect of a 3-phosphoinositide), and Inventions XVI-XVIII (method of activating protein kinase B), as well as to elicit antibodies.

5. Inventions IV-VI and VII-XVIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the nucleic acids of Inventions IV-VI are neither used nor made by the methods of Inventions VII-XVIII.

6. Inventions I-III and VII-IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the proteins of Inventions I-III are neither used nor made by the methods of purification of Inventions VII-IX. It is noted that a method of purification of the proteins of Inventions I-III is a method of use of a compound which would preferentially bind those proteins. Also, a method of purification of the proteins of Inventions I-III is not a method of making those proteins since the proteins have already being made prior to the purification process.

7. Inventions VII-XVIII are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the methods of inventions VII-XVIII comprise different steps, may use different products and produce different results.

8. As set forth in MPEP § 803, the criteria for a proper restriction between patentably distinct inventions requires that the inventions must be independent or distinct as claimed, and a search of all the inventions would impose a serious burden on the examiner. Groups I-XVIII have been shown to be independent or distinct, for the reasons set forth above. MPEP § 803 also indicates that a serious burden on the examiner may be prima facie shown if the Examiner shows by appropriate explanation either separate classification, separate status in the art, or a different field of search. The inventions of Groups I-XVIII have acquired a separate status in the art because of their recognized divergent subject matter, as shown by their different classification. In addition, a search of all the inventions would require at a minimum a separate patented/non-patented literature search, a class/subclass search, and sequence search. These searches are not all co-extensive. Therefore a comprehensive examination of all groups would impose an undue burden on the Examiner. Thus, restriction for examination purposes as indicated is proper.

9. The Examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

10. In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

11. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement can be traversed (37 CFR 1.143).

12. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

13. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available

through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Delia M. Ramirez whose telephone number is (571) 272-0938. The examiner can normally be reached on Monday-Friday from 8:30 AM to 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Ponnathapura Achutamurthy can be reached on (571) 272-0928. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Delia M. Ramirez, Ph.D.
Patent Examiner
Art Unit 1652

DR
March 13, 2006